Case Studies
Case Study: Quantifying antibody binding to HCMV-infected cell
A biopharmaceutical client needed to measure how well its anti-HCMV antibodies recognised viral antigens on the infected cell surface; something neutralisation data alone cannot show. VRS built the assay from scratch, optimising infection conditions and fixation so that high-content imaging captured surface binding only, at single-cell resolution.
Case Study: A modular ELISA platform for dengue and Zika epitope mapping
Off-the-shelf kits could not keep pace with a vaccine programme whose antigens changed with every design cycle. VRS built a platform rather than a single assay: modular enough to run direct, indirect and competition formats, and to absorb new epitopes without redevelopment.
Case Study: Validating a virus transport medium for regulatory submission
A client needed evidence that infectious virus survived 72 hours in its new transport medium, under CLSI M40-A2 plus additional FDA expectations including human mucus. VRS front-loaded the work into a pilot phase, then delivered GLP-like data across influenza, RSV and coronavirus NL63 on time.
Case Study: Iterative screening for broad-spectrum influenza antibodies
Twelve months of antibody engineering demanded functional data fast enough to steer the next design round. VRS ran high-throughput neutralisation screening through to IC₅₀ determination across multiple strains, holding measurements within a three-fold range over repeated cycles, consistency the client’s alternative readouts could not match.
Case Study: Generating a seed stock from a primary clinical isolate
Clinical isolates rarely propagate like laboratory strains. Working to a fixed timeline, VRS recovered virus from clinical material and optimised passage, culture and freezing conditions to build a characterised, quality-controlled seed stock; sufficient material for downstream work, with minimal adaptation away from the original isolate.
Case Study: From neutralisation screening to resistance characterisation
VRS supported an antibody programme through a shifting variant landscape, qualifying neutralisation assays for each new isolate from early strains through to Omicron. Serial passaging under antibody pressure then selected escape mutants, characterised by sequencing, repeat neutralisation and growth curves measuring their fitness cost.
Subscribe